Cargando…

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome

Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline’s efficacy in reducing symptoms related t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Özdener, Ayşe Elif, Rivkin, Anastasia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628681/ https://www.ncbi.nlm.nih.gov/pubmed/29033544 http://dx.doi.org/10.2147/DDDT.S127405

Ejemplares similares

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Sobolewska-Włodarczyk, Aleksandra, et al.
Publicado: (2016)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
por: Liu, Rebecca, et al.
Publicado: (2020)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea
por: Abel, Jessica L., et al.
Publicado: (2018)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
por: Mangel, Allen W, et al.
Publicado: (2012)

Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome
por: Chiba, Toshimi, et al.
Publicado: (2013)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Diarrhea-Predominant Irritable Bowel Syndrome: Medical Management Update
por: Andrews, Christopher N, et al.
Publicado: (2019)

Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity
por: Anwer, Md. Khalid, et al.
Publicado: (2023)

Efficacy and Safety of Acupoint Catgut Embedding for Diarrhea-Predominant Irritable Bowel Syndrome and Constipation-Predominant Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
por: Wu, Jing, et al.
Publicado: (2020)

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide
por: Brenner, Darren M, et al.
Publicado: (2021)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2018)

Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome
por: Li, Pingping, et al.
Publicado: (2020)

Comparison of Quality of Life and Psychiatric Symptoms Between Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Those With Constipation-Predominant Irritable Bowel Syndrome
por: BOUSABA, J., et al.
Publicado: (2023)

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
por: Nee, Judy, et al.
Publicado: (2019)

Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis
por: Guo, Jianbo, et al.
Publicado: (2020)

Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome
por: Katsumata, Ryo, et al.
Publicado: (2017)

Dysregulation of GABAergic Signalling Contributes in the Pathogenesis of Diarrhea-predominant Irritable Bowel Syndrome
por: Aggarwal, Surbhi, et al.
Publicado: (2018)

Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
por: Arrouk, Rami, et al.
Publicado: (2018)

Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome
por: Mei, Lijun, et al.
Publicado: (2021)

Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome
por: Martoni, Christopher J, et al.
Publicado: (2023)

Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
por: Anwer, Md. K., et al.
Publicado: (2017)

Metabolomics analysis of herb-partitioned moxibustion treatment on rats with diarrhea-predominant irritable bowel syndrome
por: Lin, Xianwei, et al.
Publicado: (2019)

Acupuncture for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Randomized Clinical Trial
por: Qi, Ling-Yu, et al.
Publicado: (2022)

Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial
por: Zheng, Hui, et al.
Publicado: (2016)

Claudin-2 expression is upregulated in the ileum of diarrhea predominant irritable bowel syndrome patients
por: Ishimoto, Haruka, et al.
Publicado: (2017)

Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome
por: Carroll, Ian M, et al.
Publicado: (2010)

Correlation between anxiety-depression status and cytokines in diarrhea-predominant irritable bowel syndrome
por: GAO, JINGGUO
Publicado: (2013)

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
por: Pimentel, Mark, et al.
Publicado: (2015)

Inhibitory effects of patchouli alcohol on stress-induced diarrhea-predominant irritable bowel syndrome
por: Zhou, Tian-Ran, et al.
Publicado: (2018)

Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome
por: Liu, De-Rong, et al.
Publicado: (2018)

Capsule Endoscopy in Refractory Diarrhea-Predominant Irritable Bowel Syndrome and Functional Abdominal Pain
por: Valero, Manuel, et al.
Publicado: (2018)

Effects and Mechanisms of Acupuncture on Diarrhea-Predominant Irritable Bowel Syndrome: A Systematic Review
por: Zhang, Gezhi, et al.
Publicado: (2022)

Epidemiology of Functional Diarrhea and Comparison with Diarrhea-Predominant Irritable Bowel Syndrome: A Population-Based Survey in China
por: Zhao, Yan-Fang, et al.
Publicado: (2012)

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome
por: Sayuk, Gregory S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vq2l3pej0mokulf0hohmi4iv35